Indeed, more insightful studies are needed to improve the understanding of GM-CSF-CD131 signaling in the pathogenesis of intestinal inflammation, which may shed light on an alternative avenue of IBD therapy avoiding immunosuppression. The gene discussed is CSF2RB; the disease is inflammatory bowel disease.